
Killer smog
BBC Inside Science
00:00
The Effect of Lecanamab on Alzheimer's Disease
The effect of Lecanamab is statistically significant, but its clinical significance seems to be quite small. If the effect is sustained after the 18 months trial period, patients on this drug have to come up every two weeks for infusions. We can't give people a drug that targets amyloid without knowing they've got amyloid protein in their brains. So before giving the drug, you need tests that currently 99% of patients don't get. There is a mountain to climb in terms of developing the services that can really deliver these treatments to the right patients early in the course of Alzheimer's disease.
Transcript
Play full episode